louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06815458: Visual Mind Mapping in Nursing Education
Official title: The Effect of Reflective Learning Based on Visual Mind Mapping on Developing Knowledge and Skills Regarding Vital Signs in Nursing Education: a Randomized Controlled Trial
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Education
Keywords: Mind Mapping
Nursing students
Vital signs
Lead sponsor: Bilecik Seyh Edebali Universitesi
Sponsor class: OTHER
First posted: 2025-02-07
Enrollment: 100
Sex: ALL
Minimum age (years): 17
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Nursing students

Brief summary: Visual Mind Mapping in Nursing Education

Detailed description: In this study, by using both teaching strategies in an integrated manner, it is aimed for students to grasp the information in depth and use this information effectively in a clinical environment instead of just superficial learning. The originality of the study is that it is about vital signs with first-year nursing students. It is anticipated that the study will contribute to the literature in terms of the development of knowledge-based skills such as pulse, respiration, blood pressure and body temperature.

Eligibility criteria: Inclusion Criteria:

* Receiving training on vital signs for the first time
* Being a first-year nursing student

Exclusion Criteria:

* Having previously received training on vital signs
* Having class absences, not taking the final and follow-up tests

Primary outcomes:
measure: The effect of education provided with mind mapping on success in nursing students
timeFrame: 01/11/2024-31/12/2024
Secondary outcomes:
Other outcomes:
Locations:
city: Bilecik
country: Turkey
facility: Bilecik Şeyh Edebali University
Study officials:
References:
Clinical trial NCT02872558: Shared Decision Making in Parents of Children With Acute Otitis Media
Official title: Shared Decision Making in Parents of Children With Acute Otitis Media: The Acute Otitis Media Choice Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Otitis Media
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2016-08-19
Enrollment: 101
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the efficacy of shared decision making in treatment of Acute Otitis Media in the Emergency Department setting.

Detailed description: The Investigators long-term goal is to promote evidence-based, patient-centered evaluation in the acute care setting to more closely tailor antibiotic use to disease risk for Acute Otitis Media (AOM) in children.

The Investigator will conduct a single-center cluster randomized control trial comparing the efficacy, safety and patient-centered outcomes of the shared decision-making decision aid 'Acute Otitis Media Choice' to usual care among children diagnosed with acute otitis media in the ED for whom antibiotics are being considered to engage parents in shared decision-making.

Eligibility criteria: Inclusion:

1. 6 months to 18 years in age
2. Acute Otitis Media diagnosed (AOM) at the time of visit, defined as:

   * Middle Ear Effusion- demonstrated by pneumatic otoscopy, air fluid level, or a bulging tympanic membrane PLUS
   * Evidence of Acute Inflammation- opaque, white, yellow, or erythematous tympanic membrane or purulent effusion PLUS
   * Symptoms of otalgia, fussiness or fever

Exclusion:

1. Are currently on antibiotics
2. Have acute otitis media and another diagnoses that antibiotics are prescribed for
3. Have otitis-conjunctivitis syndrome
4. Have perforation of their tympanic membrane at time of diagnoses
5. Recurrent AOM defined as:

   1. ≥3 or greater separate AOM episodes in the previous 6 months or
   2. ≥4 or more greater AOM episodes in the previous 12 months with one in the last 6 months
6. Have a craniofacial abnormality
7. Have had previous ear tubes placed
8. Have an immunologic disorder
9. Are immunosuppression either by disease or medication
10. Are undergoing treatment for cancer :

Primary outcomes:
measure: Number of parents completing the survey
timeFrame: 15 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Jana L Anderson
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00214058: Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
Official title: Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Ovarian Carcinoma
Primary Peritoneal Carcinoma
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
Collaborators: name: Aventis Pharmaceuticals
First posted: 2005-09-21
Enrollment: 36
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer


Eligibility criteria: Inclusion Criteria:

* Recurrent ovarian or peritoneal cancer

Exclusion Criteria:

* No prior chemotherapy

Primary outcomes:
measure: Safety and Efficacy
Secondary outcomes:
measure: QOL
Other outcomes:
Locations:
city: Madison
country: United States
facility: University of Wisconsin Hospital and Clinics
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: David M Kushner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00669058: Dermatological Evaluation of Topic Compatibility-Dermacyd Tina Gel Tangerina Mix
Official title: Study for Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability, Dermical Sensitivity) of Dermacyd Tina Gel Tangerina Mix.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Healthy
Keywords: hygiene
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2008-04-29
Enrollment: 52
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd Tina Gel Tangerina Mix


Eligibility criteria: Inclusion Criteria:

* Phototype Skin I,II, III e IV
* Integral skin test in the region

Exclusion Criteria:

* Lactation or gestation
* Use of Antiinflammatory and/or immunosuppression drugs
* Personnel history of atopy
* History of sensitivity or irritation for topic products
* Active cutaneous disease
* Use of new drugs or cosmetics during the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: The absence of primary and accumulated dermal irritability and dermal sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.
timeFrame: six weeks
Secondary outcomes:
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Sanofi-aventis administrative office
Study officials:
affiliation: Sanofi-aventis administrative office Brazil
name: Jaderson Lima
role: STUDY_DIRECTOR
References:
Clinical trial NCT01620658: Radioprotective Light-weight Caps in the Interventional Cardiology Setting
Official title: Radioprotective Light-weight Caps in the Interventional Cardiology Setting: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Occupational Exposure to Radiation
Keywords: Occupational Exposure to Radiation
Lead sponsor: Baptist Health South Florida
Sponsor class: OTHER
First posted: 2012-06-15
Enrollment: 197
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The primary objective of the present trial is to compare the radiation attenuation provided by XPF caps (0.5mm lead-equivalent and 0.3mm lead-equivalent) to the standard protection (fabric cap, basically no protection) as measured in % radiation attenuation) during 150 days of fluoroscopy guided cardiology interventions. The second objective is to compare the operator comfort (rated on a visual analog scale) of wearing the XPF protection caps compared to the standard fabric caps.

Detailed description: The primary objective of the present trial is to compare the radiation attenuation provided by XPF caps (0.5mm lead-equivalent and 0.3mm lead-equivalent) to the standard protection (fabric cap, basically no protection) as measured in % radiation attenuation) during 150 days of fluoroscopy guided cardiology interventions. The second objective is to compare the operator comfort (rated on a visual analog scale) of wearing the XPF protection caps compared to the standard fabric caps.

For more information please contact Dr. Raul Herrera, MD, Director Baptist Cardiac and Vascular Institute Baptist Hospital of Miami.

Eligibility criteria: Inclusion Criteria:

* Interventional Cardiologist practicing in Baptist Cardiac \& Vascular Institute
* cardiac procedure requiring C-arm fluoroscopy

Exclusion Criteria:

* Interventional Neuroradiologists and Interventional Radiologists will not be included in this study.

Primary outcomes:
measure: Radiation Attenuation in Percentage (%)
timeFrame: 1 day
measure: Absolute Radiation Exposure Outside of Cap
timeFrame: 1 day
Secondary outcomes:
measure: Operator Comfort Assessment
timeFrame: 1 day per participant, a total of 197 operator days
measure: Operator Comfort Assessment Based on Weight
timeFrame: 1 day per participant, a total of 197 operator days
Other outcomes:
Locations:
city: Miami
country: United States
facility: Baptist Hospital of Miami, Miami Cardiac and Vascular Institute
state: Florida
Study officials:
affiliation: Baptist Hospital of Miami, Miami Cardiac and Vascular Institute
name: Raul Herrera, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Uthoff H, Quesada R, Roberts JS, Baumann F, Schernthaner M, Zaremski L, Hajirawala L, Katzen BT, Staub D, Kreusch AS. Radioprotective lightweight caps in the interventional cardiology setting: a randomised controlled trial (PROTECT). EuroIntervention. 2015 May;11(1):53-9. doi: 10.4244/EIJV11I1A9.
Clinical trial NCT01720758: Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease
Official title: Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hairy Cell Leukemia
Splenic Marginal Zone Lymphoma
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2012-11-02
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who are followed up in the Haematology Department in the Emek Medical Center for Hairy Cell Leukemia or chronic lymphoproliferative disease such as Splenic Marginal Zone Lymphoma. Patients who are examined and suspected to have Hairy Cell Leukemia.

Brief summary: The presence of a specific mutation in the gene known as B-RAF has been found in patients who have Hairy Cell Leukemia. In this study this specific mutation known as V600E will be ascertained in peripheral blood samples of patients who have this disease and in a group of patients who have a similar chronic lymphoproliferative conditions such as splenic marginal lymphoma. The finding of this specific mutation will help to verify or exclude the diagnosis of Hairy Cell Leukemia and determine whether patients are in remission.


Eligibility criteria: Inclusion Criteria:

Patients over the age of 18 years -

Exclusion Criteria:

Patients less than 18 years in age or mentally defectives.

-

Primary outcomes:
measure: detection of the B-RAF V600E mutation
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04367558: Minimal Surgical Treatment for Obstructive Sleep Apnea (OSA)
Official title: Possible Efficacy of Minimal Surgical Treatment for Obstructive Sleep Apnea (OSA)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sleep Apnea Syndromes, Obstructive
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2020-04-29
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 110
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Obstructive Sleep apnea carries a variety of complications and implications. While the disease could be treated using continuous positive airway pressure (CPAP) and lifestyle changes, many patients find it difficult to adjust to the mask, and turn to surgical options. The conventional surgical options to date ranges from radical (UPPP) to individualized, with or without Drug-induced sleep endoscopy (DISE). Previous studies showed that dise directed surgery can be useful for specific conditions. No trials were found to test in-office encompassing minimal invasive surgical treatment (RF palatoplasty , RF tonsillotomy, RF turbinectomy, and RF base-of-tongue reduction) as a viable alternative..


Eligibility criteria: Inclusion Criteria:

* Patients suffering from OSA, defined as AHI \> 5

Exclusion Criteria:

* Patients who can use CPAP.
* Patients suffering from confounding factors with higher risk (Coagulation problems, Heart conditions, chronic obstructive pulmonary disease (COPD), or other dangerous conditions as decided by the surgeon)
* Patients suffering from other problems aggravating the OSA (Respiratory, Neurologic conditions)

Primary outcomes:
measure: More than 50% improvement in Apnea-Hypopnea index (AHI)
timeFrame: 6 months following the procedure
measure: More than 50% improvement in Apnea-Hypopnea index (AHI)
timeFrame: 12 months following the procedure
measure: Reduction of AHI to below 20
timeFrame: 6 months following the procedure
measure: Reduction of AHI to below 20
timeFrame: 12 months following the procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe MC,
Study officials:
References:
Clinical trial NCT00947258: Influence of Stretching on Muscle Performance
Official title: Influence of Stretching Hamstring and Quadriceps Femoral Muscles on Peak Torque and the Maximum Power of the Knee
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Muscle Strength
Keywords: Muscle Strength
Torque
Muscle Stretching Exercises
Range of Motion
Lead sponsor: Fortaleza University
Sponsor class: OTHER
First posted: 2009-07-28
Enrollment: 15
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Primary purpose: PREVENTION

Brief summary: The stretching is performed within sports to improve muscle performance and prevent muscle injury. However, recent studies are contradictory with common practice. Then raised the possibility that stretching before physical activity performed can decrease the muscle performance of healthy subjects.


Eligibility criteria: Inclusion Criteria:

* Between 18 and 30 years.
* History of at least 3 months without performing any physical activity

Exclusion Criteria:

* Recent history of injuries in lower limbs.
* Contraindication to agree with the Par-Q form.
* Make physical activity during the search
* Fails every session of stretching
* BMI above 28
* Pain in the lumbar spine
* I had muscle shortening in Test Thomas (TT) and / or test the popliteal angle (TAP)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Fortaleza
country: Brazil
facility: Gabriel Peixoto Leão Almeida
state: Ceará
Study officials:
References:
Clinical trial NCT02573558: Intraoperative Sedation and Postoperative Delirium
Official title: Prevalence of Postoperative Delirium According to the Use of Dexmedetomidine or Propofol in Elderly Patients Undergoing Orthopedic Surgery: Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Orthopedics
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2015-10-12
Enrollment: 855
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who underwent orthopedic surgery under regional anesthesia, and age of 65 years or greater

Brief summary: Delirium are common after orthopedic surgery in the elderly and are directly associated with loss of independence, reduction in the quality of life and increased mortality. The cause of postoperative delirium still remains unclear and may be multifactorial. The aim of this retrospective study is to examine prevalence of postoperative delirium according to the use of dexmedetomidine or propofol in elderly patients undergoing orthopedic surgery under regional anesthesia.


Eligibility criteria: Inclusion Criteria:

* Patients who underwent orthopedic surgery under regional anesthesia
* age of 65 years or greater

Exclusion Criteria:

* General anesthesia
* age \< 65 years
* central nervous system disease, including dementia and Parkinson's disease
* Patients who were not received sedation with propofol or dexmedetomidine during the operation

Primary outcomes:
measure: delirium
timeFrame: within 7 day postoperatively
Secondary outcomes:
measure: Wound infection
timeFrame: within 7 day postoperatively
measure: Pulmonary thromboembolism
timeFrame: within 7 day postoperatively
measure: Hospital stay
timeFrame: through study completion, an average of 7days
Other outcomes:
measure: Myocardial ischemia
timeFrame: within 7 day postoperatively
measure: Renal failure
timeFrame: within 7 day postoperatively
measure: Hepatic failure
timeFrame: within 7 day postoperatively
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi
Study officials:
References:
Clinical trial NCT00001158: Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
Official title: Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Immunologic Deficiency Syndromes
Neoplasms
Keywords: Cellular Immunity
Humoral Immunity
Immunodeficiency Disease
Lead sponsor: National Institutes of Health Clinical Center (CC)
Sponsor class: NIH
First posted: 2002-12-10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes

Brief summary: The goal of the protocol is to define the normal humoral and cellular immune responses to antigens in volunteers and to define abnormalities of these immune responses in patients with immunodeficiency diseases or cancer. In vitro assays and in vivo skin tests and immunization with antigens will be utilized.

Detailed description: The goal of the protocol is to define the normal humoral and cellular immune responses to antigens in volunteers and to define abnormalities of these immune responses in patients with immunodeficiency diseases or cancer. In vitro assays and in vivo skin tests and immunization with antigens will be utilized.

Eligibility criteria: Patients will be studied if a disorder of the immune system is suspected.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bethesda
country: United States
facility: National Cancer Institute (NCI)
state: Maryland
Study officials:
References:
citation: Nelson DL, Blaese RM, Strober W, Bruce R, Waldmann TA. Constrictive pericarditis, intestinal lymphangiectasia, and reversible immunologic deficiency. J Pediatr. 1975 Apr;86(4):548-54. doi: 10.1016/s0022-3476(75)80145-4.
Clinical trial NCT05732558: Augmented Reality Navigation System (Endosight) for the Guidance of Bone Biopsy
Official title: Assessment of Operative Time, Precision, and Safety of an Augmented Reality Navigation System (Endosight) for the Guidance of Bone Biopsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bone Lesion
Bone Tumor
Bone Infection
Lead sponsor: R.A.W. - S.R.L.
Sponsor class: INDUSTRY
First posted: 2023-02-17
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study is designed to compare a prospective arm composed of 8 patients who were prescribed a CT-Guided bone biopsy (with the aid of endosight navigation system) with a retrospective arm with a bone lesion for which a percutaneous biopsy has been performed from January 2011 to May 2022 (without endosight navigation system)
Primary purpose: DIAGNOSTIC

Brief summary: The goal of this clinical study is to evaluate the duration of the procedure, the precision (distance between the needle tip and the centre of the target), and the safety of endosight system in the guidance for bone biopsies.

Detailed description: In this study results obtained in the prospective group will be compared with those obtained in the retrospective group.

Total N° of patients: 16

PROSPECTIVE GROUP (treated WITH the guidance of endosight):

N° of patients: 8

RETROSPECTIVE GROUP (treated WITHOUT the guidance of endosight):

N° of patients: 8

Main objective of the study:

Reduction of execution times by at least 10 minutes; Reduction of the number of CT scans by at least 2 scans.

N°of hospitals involved: 2.

Duration: maximum 6 months from the date of the first enrollment.

No follow-up is expected.

Eligibility criteria: Inclusion Criteria:

* Patient with a bone lesion for which a percutaneous biopsy is indicated;
* Informed consent signed by the patient for participation in the study.

Exclusion Criteria:

* Age \< 18 years;
* Pregnant and lactating women (assessed through auto declaration of the patient)

Primary outcomes:
measure: Procedure time
timeFrame: During bone biopsy procedure (after the bone sample has been collected)
measure: Total number of CT-SCAN
timeFrame: During bone biopsy procedure (after the bone sample has been collected)
Secondary outcomes:
measure: endosight accuracy
timeFrame: During bone biopsy procedure (after the bone sample has been collected)
measure: Total radiation dose
timeFrame: During bone biopsy procedure (after the bone sample has been collected)
measure: Operator satisfaction
timeFrame: During bone biopsy procedure (after the bone sample has been collected)
measure: Side effects
timeFrame: During bone biopsy procedure (after the bone sample has been collected)
Other outcomes:
Locations:
city: Milano
country: Italy
facility: IRCCS Ospedale Galeazzi - Sant'Ambrogio
state: MI
Study officials:
References: